First Name: Hanna
Last Name: Taipaleenmäki
Member Since: 2016 (Founding member)
Institution: University Medical centre Hamburg-Eppendorf
Dr. Hanna Taipaleenmäki is a group leader in the Molecular Skeletal Biology Laboratory (MSB-Lab) at the University Medical Center Hamburg-Eppendorf in Hamburg, Germany. During her PhD studies at the University of Turku, Finland, and at the Endocrine Research Unit, Odense University Hospital, Denmark, she developed a strong interest in post-transcriptional regulation of osteoblast differentiation and bone formation by non-coding RNAs.
During her post-doctoral training at the University of Massachusetts Medical School, USA, and at the University Medical Center Hamburg-Eppendorf, Germany, she further elucidated the contribution of microRNAs in pathological bone remodeling with specific focus on cancer-induced bone disease.
Currently her research group is investigating the role of osteoblasts in breast cancer-induced metastatic bone disease. Hanna is an active member of scientific societies including the ECTS and the ASBMR and her work has been awarded several awards, fellowships and grants.
List of 5 Best Publications
- Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.https://www.ncbi.nlm.nih.gov/pubmed/30965315
- TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone.https://www.ncbi.nlm.nih.gov/pubmed/30902975
- Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.https://www.ncbi.nlm.nih.gov/pubmed/25634212
- MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo.https://www.ncbi.nlm.nih.gov/pubmed/21444814
- Targeting the Metastatic Bone Microenvironment by MicroRNAs.https://www.ncbi.nlm.nih.gov/pubmed/29780354